VIVIAN DURU: Open Payments
NPI 1447529904 · PASADENA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$576 in 18 payments from 9 companies in 2025. Trend: 2023 $186 · 2024 $266 · 2025 $576
Food & beverage: $576
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 4 | $282 |
| ABBVIE INC. | 3 | $74 |
| PFIZER INC. | 3 | $52 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $47 |
| Corcept Therapeutics | 2 | $40 |
| Astellas Pharma US Inc | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
Products named: Dexcom G6 Transmitter, DEXCOM G7 GSS (161), VRAYLAR, Kerendia, Korlym, Veozah, MOUNJARO, GEMTESA.
Industry payments across MD — which companies pay providers there.
